Analytical testing and regulatory consultancy Broughton has increased its workforce by 15% to support rising demand across nicotine, medicinal cannabis, and pharmaceutical testing. New roles have been created at Coleby House in Skipton, Yorkshire, and Oak Tree House in Lancashire. The positions include scientific roles, team leadership posts, and business development opportunities.
The expansion supports Broughton’s plans to strengthen service capabilities in 2026 by enhancing laboratory operations and commercial capacity.
Growing presence in regulated life sciences
Based in the north of England, Broughton is an established provider in regulated life sciences. Its facilities operate with Good Manufacturing Practice accreditation from the Medicines and Healthcare Products Regulatory Agency and are inspected by the US Food and Drug Administration. The Oak Tree House site in Lancashire also holds UKAS accreditation under ISO 17025 for testing competence. With more than 15 years of experience, the company works with clients across the UK, Europe, North America, Middle East, Asia, and Australia.
The recruitment drive supports scientific employment in Yorkshire and Lancashire, where demand for laboratory and regulatory expertise continues to rise. Local universities are producing graduates who are seeking technical career pathways, and Broughton’s investment provides additional opportunities. As the regional life sciences sector grows, such activity reinforces infrastructure and supports innovation in analytical testing and regulatory compliance.
Meeting market demand for evidence and planning
The expansion responds to a growing order book across analytical testing and regulatory consultancy. Companies in regulated markets, including next-generation nicotine products, medicinal cannabis and pharmaceuticals, require clearer evidencegeneration and stronger planning to meet evolving expectations for product authorisation and post-market oversight.
New hires will increase capacity for method development, validation, technical interpretation and regulatory planning. These capabilities help clients prepare coherent submissions that combine laboratory data with regulatory guidance throughout the product lifecycle. Broughton’s integrated model supports smoother progress from concept to commercial approval.
Expertise across nicotine, cannabis and pharmaceuticals
Nicotine products: Broughton specialises in e-vapour products, heated tobacco products and modern oral nicotine products. It has completed more than:
• 375,000 analytical tests
• 700 environmental assessments
• 300 toxicological profiles, to support Premarket Tobacco Product Applications in the US.
Its expertise also aligns with regulatory frameworks, such as the European Union Tobacco Products Directive.
Medicinal cannabis:Â Demand for cannabis testing continues to increase. In August 2024, Broughton launched a suite of stability testing methods at Coleby House for growers in the UK and EU. The company holds a Schedule 1 Home Office licence and performs batch release testing for cannabis flowers. This includes identification through macroscopic appearance, odour, microscopic examination, and high-performance thin-layer chromatography. These activities complement pharmaceutical quality control work undertaken since 2006, covering raw materials, active pharmaceutical ingredients, and inhaled formulations. The services help address unmet clinical needs and support Novel Food Applications in the UK and EU.
Pharmaceutical: Broughton provides support for drug-device combinations, inhalation science, and extractables and leachables analysis to safeguard patient safety. Its multi-zone ICH stability stores assist with product development and regulatory compliance. Comparator testing strengthens clients’ competitive positioning.
Strategic expansion
“This is a period of planned expansion as we grow our laboratory and consultancy teams, expand into new markets and extend our service portfolio,” said Chris Allen, chief executive officer of Broughton.
“The level of testing activity we are seeing reflects the trust our clients place in us and the pace of development in the sectors we support. We are focused on sustainable growth that maintains scientific discipline while meeting rising demand. We expect this trajectory to continue into 2026 with further developments already underway.”
Broughton has also strengthened its commercial capability to ensure laboratory delivery aligns with client strategies from early development through regulatory submissions and ongoing evidence generation. This reinforces the life sciences infrastructure in the North of England, where data quality and evidence clarity are central to market access and long-term success.
Continued investment
The company will continue investing in facilities and service offerings for clients in regulated environments. As sectors such as medicinal cannabis and next-generation nicotine evolve, Broughton’s expansion positions it to support safer and more effective products, contributing to public health goals that include tobacco harm reduction and improved therapeutic access.







